Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD
Published: Tuesday, Jan 09, 2018



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x